Aktuelle Fragen zur COVID-19-Impfung bei besonderen Patientengruppen

Abstract

1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603–15. doi:10.1056/NEJMoa2034577. 2. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2020. doi:10.1056/NEJMoa2035389. 3. Graham S P et al. Evaluation of the immunogenicity of primeboost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19.MPJ Vaccines 2020. doi: 10.1038/s41541-020-00221-3 4. Janssen Vaccines & Prevention B.V. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE). https://clinicaltrials.gov/ct2/show/ NCT04505722 5. Beigi RH, Krubiner C, Jamieson DJ, Lyerly AD, Hughes B, Riley L, et al. The need for inclusion of pregnant women in COVID-19 vaccine trials. Vaccine 2021. doi:10.1016/j.vaccine.2020.12.074. 6. STIKO. STIKO-Empfehlung zur COVID-19-Impfung; 14.01.2021. 7. Department of Health and Social Care / UK. COVID-19 vaccination: a guide for women of childbearing age, pregnant or breastfeeding. 2021. https://www.gov.uk/government/publications/ covid-19-vaccination-women-of-childbearing-age-currentlypregnant-planning-a-pregnancy-or-breastfeeding/covid19-vaccination-a-guide-for-women-of-childbearing-agepregnant-planning-a-pregnancy-or-breastfeeding. Accessed 17 Jan 2021. 8. SMFM. SARS-CoV-2 Vaccination in Pregnancy; 01.12.2020. 9. CDC. Vaccination Considerations for People who are Pregnant or Breastfeeding. 2021. https://www.cdc.gov/coronavirus/2019ncov/vaccines/recommendations/pregnancy.html. Accessed 25 Jan 2021. 10. Gao Y, Chen Y, Liu M, Shi S, Tian J. Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis. J Infect. 2020;81:e93-e95. doi:10.1016/j. jinf.2020.05.017. 11. RKI. Beschluss der STIKO zur 1. Aktualisierung der COVID19-Impfempfehlung; 02/2021. 12. Wagner N, Assmus F, Arendt G, Baum E, Baumann U, Bogdan C, et al. Impfen bei Immundefizienz : Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (IV) Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entzündlichen Erkrankungen und unter immunmodulatorischer Therapie. Bundesgesundheitsbl. 2019;62:494–515. doi:10.1007/s00103-019-02905-1. 13. DGRh e.V. Impfung gegen SARS-CoV-2 bei entzündlich-rheumatischen Erkrankungen. 01.12.2020. https://dgrh.de/Start/ Wissenschaft/Forschung/COVID-19/Impfung-gegen-SARSCoV2.html. Accessed 26 Jan 2020. 14. Laws H-J, Baumann U, Bogdan C, Burchard G, Christopeit M, Hecht J, et al. Impfen bei Immundefizienz : Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie. Bundesgesundheitsbl. 2020;63:588–644. doi:10.1007/s00103-02003123-w. 15. Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, et al. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clinical and experimental immunology. 2020;202:149–61. doi:10.1111/cei.13495. 16. Gresham LM, Marzario B, Dutz J, Kirchhof MG. An EvidenceBased Guide to SARS-CoV-2 Vaccination of Patients on Immunotherapies in Dermatology. Journal of the American Academy of Dermatology 2021. doi:10.1016/j.jaad.2021.01.047. 17. DHGO. Positionspapier: COVID-19 Schutzimpfung bei Patienten mit aktiver Krebserkrankung; 27.01.2021. 18. Hall V, Foulkes S, Charlett A, Atti A, Monk EJ, Simmons R, et al. Do antibody positive healthcare workers have lower SARSCoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020; 2021. 19. Public Health England. COVID-19 vaccination programme: Information for healthcare practitioners. 3rd ed.; 11.01.2021. 20. CDC. Centers for Disease Control and Prevention (CDC). 2021. CDC. Accessed 22 Jan 2021. 21. WHO. Who can take the Pfizer-BioNTech COVID-19 vaccine? 25.01.2021. https://www.who.int/news-room/feature-stories/ detail/who-can-take-the-pfizer-biontech-covid-19--vaccine. Accessed 25 Jan 2021. 22. Weissman D, Alameh M-G, Silva T de, Collini P, Hornsby H, Brown R, et al. D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. Cell Host & Microbe. 2021;29:2331.e4. doi:10.1016/j.chom.2020.11.012. 23. Xie X, Zou J, Fontes-Garfias CR, Xia H, Swanson KA, Cutler M, et al. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. bioRxiv 2021. doi:10.1101/2021.01.07.425740. 24. Muik A, Wallisch A-K, Sänger B, Swanson KA, Mühl J, Chen W, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera; 2021. 25. Wu K, Werner AP, Moliva JI, Koch M, Choi A, Stewart-Jones GBE, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv. 2021:2021.01.25.427948. doi:10.1101/2021.01.25.427948. 26. Emary K et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7). The Lancet 2021; doi: 10.2139/ssrn.3779160. 27. Callaway E. Could new COVID variants undermine vaccines? Labs scramble to find out. Nature. 2021;589:177–8. doi:10.1038/d41586-021-00031-0. F O R T B I L D U N G